These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 2127807

  • 1. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
    Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS, Satyamurthy N, Mazziotta JC, Phelps ME.
    J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
    [Abstract] [Full Text] [Related]

  • 2. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA.
    Endres CJ, DeJesus OT, Uno H, Doudet DJ, Nickles JR, Holden JE.
    Front Biosci; 2004 Jan 01; 9():505-12. PubMed ID: 14766386
    [Abstract] [Full Text] [Related]

  • 3. 6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography.
    Melega WP, Hoffman JM, Schneider JS, Phelps ME, Barrio JR.
    Brain Res; 1991 Mar 15; 543(2):271-6. PubMed ID: 1905578
    [Abstract] [Full Text] [Related]

  • 4. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
    Doudet DJ, Chan GL, Holden JE, McGeer EG, Aigner TA, Wyatt RJ, Ruth TJ.
    Synapse; 1998 Jul 15; 29(3):225-32. PubMed ID: 9635892
    [Abstract] [Full Text] [Related]

  • 5. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.
    Melega WP, Grafton ST, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.
    J Cereb Blood Flow Metab; 1991 Nov 15; 11(6):890-7. PubMed ID: 1939384
    [Abstract] [Full Text] [Related]

  • 6. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T, Condé F, Grégoire MC, Frouin V, Coulon C, Fuseau C, Hinnen F, Dollé F, Hantraye P, Bottlaender M.
    J Cereb Blood Flow Metab; 2001 Jul 15; 21(7):782-92. PubMed ID: 11435790
    [Abstract] [Full Text] [Related]

  • 7. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS, Comi G, Bankiewicz K, Plunkett R, Adams R, Di Chiro G, Kopin IJ.
    Brain Res; 1993 Oct 29; 626(1-2):1-13. PubMed ID: 8281420
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S, Tsukada H.
    J Nucl Med; 2016 Feb 29; 57(2):303-8. PubMed ID: 26564319
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
    Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, Ruth TJ, Holden JE.
    J Cereb Blood Flow Metab; 1999 Mar 29; 19(3):278-87. PubMed ID: 10078880
    [Abstract] [Full Text] [Related]

  • 10. The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans.
    Melega WP, Hoffman JM, Luxen A, Nissenson CH, Phelps ME, Barrio JR.
    Life Sci; 1990 Mar 29; 47(2):149-57. PubMed ID: 2117691
    [Abstract] [Full Text] [Related]

  • 11. Comparative assessment of 6-[18 F]fluoro-L-m-tyrosine and 6-[18 F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model.
    Becker G, Bahri MA, Michel A, Hustadt F, Garraux G, Luxen A, Lemaire C, Plenevaux A.
    J Neurochem; 2017 May 29; 141(4):626-635. PubMed ID: 28294334
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
    Melega WP, Raleigh MJ, Stout DB, DeSalles AA, Cherry SR, Blurton-Jones M, Morton GG, Huang SC, Phelps ME.
    Exp Neurol; 1996 Oct 29; 141(2):318-29. PubMed ID: 8812167
    [Abstract] [Full Text] [Related]

  • 13. Biological imaging and the molecular basis of dopaminergic diseases.
    Barrio JR, Huang SC, Phelps ME.
    Biochem Pharmacol; 1997 Aug 01; 54(3):341-8. PubMed ID: 9278092
    [Abstract] [Full Text] [Related]

  • 14. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
    Wahl L, Nahmias C.
    J Nucl Med; 1996 Mar 01; 37(3):432-7. PubMed ID: 8772639
    [Abstract] [Full Text] [Related]

  • 15. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
    Huang SC, Yu DC, Barrio JR, Grafton S, Melega WP, Hoffman JM, Satyamurthy N, Mazziotta JC, Phelps ME.
    J Cereb Blood Flow Metab; 1991 Nov 01; 11(6):898-913. PubMed ID: 1939385
    [Abstract] [Full Text] [Related]

  • 16. 6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.
    Doudet DJ, Wyatt RJ, Cannon-Spoor E, Suddath R, McLellan CA, Cohen RM.
    J Neural Transplant Plast; 1993 Nov 01; 4(1):27-38. PubMed ID: 7509198
    [Abstract] [Full Text] [Related]

  • 17. Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
    Chiueh CC, Firnau G, Burns RS, Nahmias C, Chirakal R, Kopin IJ, Garnett ES.
    Adv Neurol; 1987 Nov 01; 45():167-9. PubMed ID: 3103385
    [No Abstract] [Full Text] [Related]

  • 18. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
    Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR.
    Mov Disord; 2001 Sep 01; 16(5):838-48. PubMed ID: 11746613
    [Abstract] [Full Text] [Related]

  • 19. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS.
    Front Biosci; 2003 Sep 01; 8():a155-66. PubMed ID: 12957824
    [Abstract] [Full Text] [Related]

  • 20. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
    Hoffman JM, Melega WP, Hawk TC, Grafton SC, Luxen A, Mahoney DK, Barrio JR, Huang SC, Mazziotta JC, Phelps ME.
    J Nucl Med; 1992 Aug 01; 33(8):1472-7. PubMed ID: 1634937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.